Claudio Mussolino

Claudio Mussolino, PhD
+49 761 270-77738

The Junior Group "Genome Engineering" focuses on the use of designer nuclease platforms based on TALENs and CRISPR-Cas9, to develop novel therapeutics for primary immunodeficiency and HIV infection. In parallel, our research aims at establishing novel tools for gene therapy as designer transcription factors or chromatin modifiers that can be used to control gene expression with therapeutic purpose. Our ultimate goal is the application of these technology for human gene therapy.